What it is
A synthetic chain of 15 amino acids, based on a sequence identified in human gastric juice. “BPC” stands for Body Protection Compound — a name given by the original research group, describing what they set out to investigate rather than a proven conclusion.
Notable
Unusually stable in stomach acid. Published reviews describe it remaining intact in gastric juice beyond 24 hours, where most peptides break down in minutes. That single property is the reason an oral capsule format is viable at all.
What research looked at
Investigated primarily in rodent models since the early 1990s, with study endpoints focused on the gastrointestinal tract, and on soft-tissue and tendon repair. One 2024 review collected over 130 published papers.
Evidence
Animal research — extensiveHuman trials — very limited
Not established
Long-term human safety, effective human dosing, and how much of an oral dose reaches the bloodstream have not been established. Its proposed mechanism involves promoting new blood vessel growth, which is also relevant to tumour growth — raised in the literature as a theoretical caution, not a demonstrated effect.
Where the name comes from
The nickname came from animal tissue-repair studies, amplified by podcasts and forums. It is not a scientific term.
Formats we carry
Two formats of the same sequence.
Oral capsules rely on the acid-stability described above and are the simpler starting point — nothing to prepare. The
lyophilised vial is the injectable research format: a sealed vial of freeze-dried peptide that a lab reconstitutes itself with
bacteriostatic water before use (sold separately), delivering the peptide directly rather than through the digestive tract. Neither format changes what is or isn’t established about the compound itself.